secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2026-10-06T13:11:23+00:00
Accession:  0001193125-26-415012
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Repligen closes BioLife acquisition; holders get $11.25 cash plus 0.1442 Repligen shares
--------------------------------------------------------------------------------

- Merger completed Oct 6, 2026 under the July 21, 2026 agreement; BioLife shareholders received $11.25 cash plus 0.1442 Repligen shares per share.
- Special meeting Oct 5, 2026: merger adopted 40,910,337 for vs 83,451 against; 48,923,333 shares outstanding at Sept 3 record date; 83.79% represented.
- Advisory vote on merger-related named-executive compensation passed 35,037,565 for vs 5,914,889 against; the adjournment proposal was moot.
- All 7 BioLife directors (de Greef, Coste, DuRoss, Ellingson, Goswami, Hunt, Moore) and NEOs (de Greef, Wichterman, Mathew, Berard, Warner) exited at the effective time.
- BioLife options, RSUs, PSUs and restricted stock accelerated and vested in full; Nasdaq trading suspended Oct 6 with Form 25 delisting and Form 15 deregistration planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000119312526415012/0001193125-26-415012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000119312526415012/d753652d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-415012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer